IDiyas

For the Inventor, By the Inventor

Westborough, MA, United States of America

John Goodchild

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.7

ph-index = 5

Forward Citations = 76(Granted Patents)


Company Filing History:

goldMedal11 out of 98 
 
Hybridon, Inc.
 patents

Years Active: 1996-2006

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6984729 - Oligonucleotides specific for hepatitis B virus (2006-01-10),
2. 6509149 - HPV-specific oligonucleotides (2003-01-21),
3. 6458940 - HPV-specific oligonucleotides (2002-10-01),
4. 5856459 - Oligonucleotides specific for hepatitis B virus (1999-01-05),
5. 5700923 - Finderons and methods of their preparation and use (1997-12-23),
6. 5679555 - Method of using ribozyme analogs having rigid, non-nucleotidic molecular (1997-10-21),
7. 5679554 - Finderons and methods of their preparation and use (1997-10-21),
8. 5650502 - Ribozyme analogs having rigid non-nucleotidic linkers (1997-07-22),
9. 5646021 - Finderons and methods of their preparation and use (1997-07-08),
10. 5627055 - Finderons and methods of their preparation and use (1997-05-06),
11. 5545729 - Stabilized ribozyme analogs (1996-08-13),

Title: The Innovations of John Goodchild

Introduction

John Goodchild is a prominent inventor based in Westborough, MA (US), known for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, Goodchild has made remarkable advancements in the development of synthetic oligonucleotides, particularly in relation to viral infections.

Latest Patents

Among his latest patents, Goodchild has developed oligonucleotides specific for the hepatitis B virus. This invention discloses synthetic oligonucleotides that are complementary to both contiguous and noncontiguous regions of the HBV RNA. The patent also includes methods and kits designed to inhibit the replication and expression of HBV, as well as to treat HBV infections and associated conditions. Another notable patent involves HPV-specific oligonucleotides, which are synthetic oligonucleotides complementary to a nucleic acid that spans the translational start site of the human papillomavirus gene E1. This invention includes methods and kits for inhibiting the replication of HPV, detecting HPV, and treating HPV infections.

Career Highlights

Goodchild's career has been marked by his work at Hybridon, Inc., where he has played a crucial role in advancing research and development in the field of oligonucleotide therapeutics. His innovative approaches have contributed to the understanding and treatment of viral infections, showcasing his expertise and dedication to scientific progress.

Collaborations

Throughout his career, Goodchild has collaborated with notable colleagues, including Thomas E Leonard and Peter C Roberts. These partnerships have further enhanced his research efforts and have led to significant advancements in the field.

Conclusion

John Goodchild's contributions to biotechnology, particularly in the development of oligonucleotides for viral infections, highlight his innovative spirit and commitment to improving healthcare solutions. His work continues to influence the field and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…